Haematologica 2016 Jun 16

Maintenance rituximab following induction R-CHOP chemotherapy in patients with composite or discordant, indolent and aggressive, B-cell non-Hodgkin lymphomas.

Related Questions

Would you offer maintenance lenalidomide or rituximab in a patient with DLBCL transformed from a marginal zone lymphoma in a young, fit patient?

Medical Oncology · Mayo Clinic College of Medicine and Science (Scottsdale)

No. There is no role for maintenance therapy in aggressive lymphomas (transformed or not). This is based on the assumption that DLBCL is curable and randomized trials evaluating maintenance therapy in de novo disease did not show an improvement in survival (see HOVON Nordic trial). Dedicated trials ...